Reminder of Class Action Lawsuit for Embecta Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 11 hours ago
0mins
Source: Globenewswire
- Declining Financial Performance: Embecta reported a more than 14% revenue decline in its Q2 2026 financial results, primarily due to weak pen needle sales, which led the company to lower its guidance for the fiscal year 2026, directly impacting investor confidence.
- Stock Price Plunge: Following the earnings report on May 5, 2026, Embecta's stock price fell by $5.35, a staggering 57.8% drop, closing at $3.90 per share, resulting in significant losses for investors.
- Class Action Context: The class action lawsuit against Embecta alleges that the company made materially false statements and failed to disclose adverse facts about its business and prospects during the class period, severely undermining investor trust in the company's future.
- Legal Action Deadline: Investors must file a lead plaintiff motion by August 17, 2026, to participate in the class action lawsuit and seek recovery for their investment losses, ensuring their legal rights are protected.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EMBC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EMBC
About EMBC
Embecta Corp. is a global medical device company. It provides solutions to improve the health and well-being of people living with diabetes. Its portfolio of marketed products, including a variety of pen needles, syringes and safety injection devices. Its pen needles are sterile, single-use, medical devices, designed to be used in conjunction with pen injectors that inject insulin or other diabetes medications. It sells safety pen needles, which have shields on both ends of the cannula that automatically deploy after the injection to help prevent needlestick exposure and injury during injection and disposal. Its traditional and safety pen needles are compatible and frequently used with pen injectors in the market. It sells sterile, single-use insulin syringes, which are used to inject insulin drawn from insulin vials. It distributes its products through channels, including retail, hospitals and pharmacies. It is also a manufacturer of medical devices and drug delivery technologies.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Stock Plunge Reason: Embecta's stock plummeted 57.8% on May 5, 2026, dropping from $9.25 to $3.90 per share due to disappointing Q2 results, primarily driven by a loss of market share in its pen needle product category, raising serious concerns among investors about the company's outlook.
- Legal Action Initiated: A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP against Embecta and certain executives for alleged securities fraud, with investors required to apply by August 17, 2026, to lead the case, indicating potential reputational risks for the company.
- Market Competition Pressure: While Embecta previously claimed its insulin pen portfolio was performing well, the lawsuit alleges that the company is actually facing significant competition and overall market softness, which may exacerbate investor concerns regarding its future performance.
- Dividend Cut: Embecta slashed its quarterly dividend from $0.15 to $0.01 per share, reflecting financial strain and potentially leading to further declines in investor confidence, which could adversely affect its stock price and market performance.
See More

- Lawsuit Background: Embecta Corp. is facing a securities class action lawsuit due to its disappointing Q2 2026 earnings report, with the class period spanning from November 25, 2025, to May 4, 2026, highlighting severe investor disillusionment regarding the company's future prospects.
- Deteriorating Financial Performance: The company reported an adjusted EPS of only $0.27 for Q2 2026, representing a staggering year-over-year decline of approximately 61%, starkly contrasting with prior earnings guidance and leading to a significant drop in stock price, severely undermining investor confidence.
- Severe Market Reaction: Following the earnings report, Embecta's stock plummeted, with analysts emphasizing the need for the management to rebuild investor trust, particularly regarding transparency in commercial execution and profitability outlook.
- Legal Investigation Initiated: Hagens Berman has launched an investigation focusing on whether Embecta was aware of market weaknesses prior to the earnings report, and if misleading statements were made, which could expose the company to greater legal liabilities.
See More
- Lawsuit Initiation: Faruqi & Faruqi LLP is investigating potential claims against Embecta Corp. and reminds investors to apply for lead plaintiff status by August 17, 2026, to participate in the federal securities class action against the company.
- Severe Performance Decline: Embecta's Q2 2026 results, released on May 5, 2026, revealed a revenue drop of over 14%, significantly worse than the expected flat to a 2% decline, necessitating a downward revision of its fiscal 2026 guidance due to weak pen needle sales.
- Stock Price Plummet: Following the disappointing earnings report, Embecta's stock price fell dramatically from $9.25 per share on May 4, 2026, to $3.90 per share, marking a staggering decline of over 57.8% in a single day, severely impacting investor confidence.
- Investor Rights Protection: Faruqi & Faruqi encourages investors who purchased Embecta shares between November 25, 2025, and May 4, 2026, to contact them promptly to discuss their legal rights and potential claims, ensuring their interests are protected in the class action lawsuit.
See More
- Class Action Notice: Rosen Law Firm reminds investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, to apply as lead plaintiffs by August 17, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue compensation without financial burden.
- Lawsuit Background: The lawsuit alleges that Embecta made false or misleading statements regarding its financial results, leading to investor losses when the company failed to meet expectations and cut its 2026 fiscal guidance, highlighting significant management failures.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and resource advantages in handling such cases.
See More

- Lawsuit Background: Embecta Corp. is facing a securities class action lawsuit following its disastrous Q2 2026 earnings report, which represents investors who purchased stock between November 25, 2025, and May 4, 2026, highlighting severe investor concerns regarding the company's financial health.
- Deteriorating Financial Performance: The company reported an adjusted EPS of only $0.27 for Q2 2026, a staggering year-over-year decline of approximately 61%, starkly contrasting with prior guidance of $2.80 to $3.00 for 2026, leading to a significant drop in market confidence regarding its future profitability.
- Severe Market Reaction: Following the earnings report, Embecta's stock price plummeted, with analysts noting that the management needs to rebuild investor credibility regarding commercial execution and profitability outlook, reflecting market skepticism about the company's transparency and risk management.
- Significant Dividend Cut: Embecta slashed its 2026 adjusted EPS guidance to $1.55 to $1.75 and reduced its dividend by 93% to just $0.01, indicating financial strain in addressing market challenges and insufficient commitment to shareholder returns.
See More
- Class Action Filed: Bronstein, Gewirtz & Grossman LLC has initiated a class action lawsuit against Embecta Corp, alleging violations of federal securities laws during the period from November 25, 2025, to May 4, 2026, seeking damages for affected investors.
- False Statements Allegations: The complaint claims that Embecta made materially false and misleading statements about its business, particularly asserting that its pen needle business was 'incredibly resolute' just weeks before it missed expectations and cut its fiscal guidance for 2026.
- Revenue Decline: Embecta's Q2 2026 results revealed a revenue decline of over 14%, significantly worse than its guidance of flat to a 2% decline, indicating substantial weaknesses in its U.S. performance, particularly in pen needle sales.
- Investor Action Encouraged: Affected investors are urged to apply to be lead plaintiffs by August 17, 2026, to participate in any potential recovery, with the law firm operating on a contingency fee basis, thus minimizing financial risk for investors.
See More






